Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8925 | 0.75 | MAOA (0.39) | MAOAMAOB | |
| SCHEMBL31513481 | 0.75 | MAOA (0.39) | MAOAMAOB | |
| Methylamine SCHEMBL6415772 | 0.74 | MAOA (0.35) | MAOAMAOB | |
| SCHEMBL7679301 | 0.74 | MAOA (0.38) | MAOAMAOB | |
| Hydrochloric Acid SCHEMBL8707066 | 0.74 | MAOA (0.38) | MAOAMAOB | |
| Methane SCHEMBL28285761 | 0.74 | MAOA (0.38) | MAOAMAOB | |
| Water SCHEMBL15284972 | 0.74 | MAOA (0.38) | MAOAMAOB | |
| Hydrochloric Acid SCHEMBL8699855 | 0.74 | MAOA (0.38) | MAOAMAOB | |
| SCHEMBL3927587 | 0.73 | — | — | |
| SCHEMBL5525165 | 0.69 | MAOA (0.38) | MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101829328-B | Medicine for treating amphetamine type stimulant dependency and mixed dependency of amphetamine type stimulant dependency and opium | LU ZHENGTANG | 2014-02-12 | — | — | CN | claimed |
| CN-103495172-A | Medicament for treating amphetamine type stimulant dependency and mixed dependency of amphetamine type stimulants and opiates substances | LU ZHENGTANG | 2014-01-08 | — | — | CN | claimed |
| CN-101829328-A | Medicine for treating amphetamine type stimulant dependency and mixed dependency of amphetamine type stimulant dependency and opium | ZHENGTANG LU | 2010-09-15 | — | — | CN | claimed |
| CN-101804197-A | Medicament compound for treating cancer bone metastasis and purposes thereof | HUA WEI | 2010-08-18 | — | — | CN | claimed |
| CN-101277684-A | Microparticles for the modified release of at least one active principle and oral pharmaceutical forms containing them | FLAMEL TECH SA (FR) | 2008-10-01 | — | — | CN | claimed |
| CN-1267087-C | Pharmaceutical tablet | PHARMACIA CORP (US) | 2006-08-02 | — | — | CN | claimed |
| CN-1259974-C | Drug giving-up medicine made-up by non-thebaica medicines | YONG WEICHANG (CN) | 2006-06-21 | — | — | CN | claimed |
| CN-1630512-A | Pharmaceutical tablet | PHARMACIA CORP (US) | 2005-06-22 | — | — | CN | claimed |
| CN-1579551-A | Drug giving-up medicine made-up by non-thebaica medicines | YONG WEICHANG (CN) | 2005-02-16 | — | — | CN | claimed |
| CN-1160071-C | Use of substituted 2,4-imidazolidinedione compounds as analgesics | — | 2004-08-04 | — | — | CN | claimed |
| EP-1144369-B1 | ACETYLENIC ARYL SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | WYETH CORP (US) | 2004-07-21 | — | — | EP | claimed |
| CN-1157201-C | Composite non-opium medicine for dropping drugs | 卢正堂 | 2004-07-14 | — | — | CN | claimed |
| US-6762178-B2 | FOR USE IN TREATMENT OF DISEASE CONDITIONS MEDIATED BY TNF-ALPHA, SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, SEPSIS, AIDS, ULCERATIVE COLITIS, MULTIPLE SCLEROSIS, CROHN'S DISEASE, DEGENERATIVE CARTILAGE LOSS | WYETH HOLDINGS CORPORATION | 2004-07-13 | — | — | US | claimed |
| US-20010056088-A1 | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors | AMERICAN CYANAMID COMPANY (US) | 2001-12-27 | — | — | US | claimed |
| EP-1144369-A2 | ACETYLENIC ARYL SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-17 | — | — | EP | claimed |
| CN-1313108-A | Composite non-opium medicine for dropping drugs | LU ZHENGTANG (CN) | 2001-09-19 | — | — | CN | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| WO-2000044710-A2 | ACETYLENIC ARYL SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | claimed |
| CN-1083383-A | Analgesic health-care plaster for external use and compound method thereof | HAICHENG CITY INST OF APPLIED (CN) | 1994-03-09 | — | — | CN | claimed |
| US-4318909-A | Benzoxazocines | JOHN WYETH & BROTHER LIMITED (GB) | 1982-03-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056088-A1 | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors | PTDSS1, SAT1, TNF | MAOA 2367/4885MAOB 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.